Navigation Links
Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results
Date:11/10/2009

NEW HAVEN, Conn., Nov. 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced financial results for the three-month and nine-month periods ending September 30, 2009.

For the third quarter of 2009, the Company reported a net loss of $6.2 million, or $0.78 per share, compared with a net loss of $6.8 million, or $0.92 per share, for the same 2008 period. Weighted-average common shares outstanding for the three-month periods ended September 30, 2009 and 2008 were 8.0 million and 7.4 million, respectively.

For the nine-month period, the net loss was $17.1 million, or $2.15 per share, compared with a net loss of $22.9 million, or $3.12 per share, for the same 2008 period. Weighted-average common shares outstanding for the nine-month periods ended September 30, 2009 and 2008 were 8.0 million and 7.4 million, respectively.

In the quarter, the Oncologic Drugs Advisory Committee (ODAC), which is the cancer drug advisory panel of the U.S. Food and Drug Administration (FDA), voted in favor of requiring Vion to complete a randomized study defining the efficacy and safety of the Company's lead oncology therapeutic Onrigin(TM) (laromustine) Injection prior to receiving regulatory approval from the FDA. Vion currently does not have the funds to conduct such a randomized trial.

On October 12, 2009, the Company announced it had hired the investment banking firm Merriman Curhan Ford & Co. to assist in evaluating its strategic alternatives. These alternatives include any combination of a restructuring of the Company and its debt and a sale of the Company or its assets. The Company may also consider financing options. The Company expects its strategic review to be completed in the fourth quarter of 2009. The outcome of the Company's strategic review will determine whether the Company continues operations or whether it curtails or ceases operations, liquidates its assets and/o
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
2. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
3. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
4. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
5. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
7. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
8. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
9. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
10. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
11. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... NATICK, Mass., Feb. 7, 2012 Boston Scientific Corporation (NYSE: ... Leerink Swann 2012 Global Healthcare Conference on February 15 in ... Mahoney, President, and Jeff Capello, Executive Vice President and Chief ... session regarding the Company beginning at approximately 11:00 a.m. ET. ...
... Feb. 7, 2012  Cardica, Inc. (Nasdaq: CRDC ) today ... and other conditions, shares of its common stock in an underwritten ... when the offering may be completed, or as to the size ... is acting as sole book-running manager for the offering. ...
Cached Medicine Technology:Boston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference 2Cardica Announces Proposed Public Offering of Common Stock 2
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... Radioimmunotherapy is a technique used in treating cancer , in ... are injected into patients.// These antibodies target and destroy ... particles . The main advatage of this treatment is ... ,A study in mice showed that this approach could be ...
... some of the reasons why hundreds of people// in ... to orthopaedic experts here. ,"Indian orthopaedics is ... complicated surgeries being performed here daily," said Surya Bhan, ... Institute of Medical Sciences (AIIMS) here. ,Bhan ...
... of deaths due to alcoholism has raised twofold in the ... that the number of deaths due to alcohol was 4,144 ... by last year. ,According to the experts, the lower ... alcohol consumption. Premature deaths are mainly caused by binge drinking ...
... been shown to prevent 70 per cent of cervical ... according to reports from Labor today. ,The government's ... Australian manufacturer CSL to make the vaccine Gardasil freely ... ,Gardasil, the vaccine designed in Australia halts the ...
... cells trial will be conducted within weeks on 100 patients ... yesterday.// ,This ?1.2 million trial of stem cells ... marrow will be backed by ?500,000 from philanthropists and aims ... of prompt action to cut deaths and suffering. ...
... such as ranitidine (Zantac) and cimetidine (Tagamet)and proton pump ... to increase the risk of cancer of the esophagus or ... H2 blockers and proton pump inhibitors do not increase the ... probably due to other related factors. 'There have been concerns ...
Cached Medicine News:Health News:A New Option For AIDS Treatment - Radioimmunotherapy 2Health News:Mismanagement of fractures a major concern, say experts 2Health News:Deaths due to heavy drinking has doubled in 15 years 2Health News:Heart Attack Damage Repaired with Stem cells 2Health News:Long-time Gastric Acid Suppression Does Not Increase The Risk Of Cancer 2
... Compensating for movement is ... in wheelchairs. Thats why ... exclusive technology to do ... with state-of-the-art technology, these ...
... wheelchair scale accommodates standard to extra-wide wheelchairs ... devices. The low-profile, heavy-duty, anodized aluminum weighing ... 1/2" high providing easy access for large ... stainless steel digital readout. The 6772 has ...
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: